Fig 3. Blocking DHODH with brequinar reduced reduces glioblastoma tumor xenografts growth in vivo.

(A) Representation of the subcutaneous xenograft experiment using LN229 cells. Mice were treated with 10 mg/kg brequinar with daily intraperitoneal injections (IP). (B) Tumor volume measurements of LN229 xenografts once the tumors reached 100 mm³. (C) Tumor weight of LN229 xenografts at day 60 (end of experiment). See also Supplementary S5B and S5C Fig. (D) Representative xenograft tumors from control and brequinar-treated mice. See also Supplementary S5B Fig. (E) Mouse weights at day 60 before the tumors were harvested. (F) Three representative control and brequinar-treated LN229 xenografts tumors showing increased blood vascularity in the control group (left panel) and qPCR for VEGFA in the LN229 xenografts. (G) Western blot of 5 control and brequinar-treated LN229 xenograft tumors for DHODH, p53, acetyl-tubulin, and HIF1α. * indicates p-values ≦ 0.05. Numerical values for each of the experiments represented are available in S3 Data.